Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

<p>Abstract</p> <p>Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years, TLS has been more widely observed...

Full description

Bibliographic Details
Main Authors: McBride Ali, Westervelt Peter
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Journal of Hematology & Oncology
Subjects:
Acute renal failure
Allopurinol
Adverse events
Hematologic malignancies
Management
Prophylactic therapy
Solid tumors
Tumor lysis syndrome (TLS)
Rasburicase
Uric acid
Online Access:http://www.jhoonline.org/content/5/1/75

Internet

http://www.jhoonline.org/content/5/1/75

Similar Items